AbbVie And Biogen Make ICER's Unsupported Price Increase List Three Years Running
Executive Summary
ICER's report on unsupported price increases highlighted seven drugs that cost the US health system $1.67bn due to price increases after rebates and other concessions.
You may also be interested in...
Drugs From Bausch, J&J And Amgen Top ICER's Unsupported Price Increase List
Seven of the top 10 drugs with net price increases in 2021 that had a substantial effect on US spending did not have adequate new evidence to support any price increase, ICER determined.
Tecfidera Headwinds Could Mean Cuts At Biogen, Unless Aducanumab Succeeds
Biogen lowered revenue guidance for the year by $600m due to Tecfidera generics and said it could consider broader cost cuts in 2021 depending on the outcome of aducanumab at the US FDA.
In US Drug Pricing Debate, ICER’s Voice Gets Louder
ICER’s influence on drug pricing, and policy, is growing. Spotlighting the worst drug price rises is one recent example.